Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Medigene, Memphasys, Qiagen - which stocks belong in the portfolio?

Mario Hose Mario Hose, news.financial
0 Comments| March 4, 2020

{{labelSign}}  Favorites
{{errorMessage}}

In times of price fluctuations, so-called 'buy on dips' strategy can be an effective method of achieving a favorable entry price for listed companies. Global trends as a framework can be decisive for a successful investment decision. For a modern society, the healthcare sector has become a particularly important sector. In addition to the desire for a long life with health and care, there is also an increasing demand for products and therapies that can fulfil couples' desire to have children. There is a broad spectrum and as an investor it is worth taking a look at the companies.


In the fight against cancer

The name Medigene (FSE: MDG1) is certainly known to many traders. The German biotech company is engaged in therapies for the treatment of various types of cancer in different stages. The T-cell-focused immune therapies are the focus of Medigene. Starting in the field of blood cancers, the company is pursuing a strategy of initiating its own clinical development programmes.

In addition, therapeutic approaches are being sought with selected partners to enable successful treatment of tumors. The market value of Medigene is currently around EUR 110 million. The Medigene share is an investment in cancer research.


Increasing the chances of having children

More and more couples worldwide are desperately longing in vain for a child of their own. Modern medicine has developed various possibilities and procedures to successfully initiate pregnancy. The so-called in vitro fertilisation, also known as IVF procedure, is one possibility of artificial insemination. In this procedure, the ovum is taken from the woman and then artificially fertilized with the man's sperm in the laboratory. If the fertilization is successful, the embryos can then be transferred to the uterus so that pregnancy can begin.

In order to increase the chances of a successful pregnancy, the separation of high-quality sperm is purposeful. The Australian company Memphasys (ASX: MEM) has developed a product that can be used to process the seminal fluid to increase the birth rate. The product called FELIX is currently being tested by experts and sales are expected to start in the second half of 2020. Memphasys currently has a market value of around EUR 25 million. The Memphasys shares enable investors to support couples' desire to have children and benefit from the success of the product.


Expert in molecular information

In connection with the current corona virus, the biotech company Qiagen (NYSE: QGEN) can offer test solutions that can diagnose whether a patient is infected within an hour. The company is represented in 25 countries around the globe and employs 4,700 people.

According to Medigene, the company offers 500 products that enable physicians, scientists and laboratory staff to examine and research the molecules of the human body for various purposes. The company has more than 500,000 customers in its more than 30-year history. The market value of Qiagen is currently EUR 7.3 billion. Qiagen's stock is the focus of the hype surrounding the current corona virus and a takeover bid by Thermo Fisher. Investors can see price gains.


CONFLICT OF INTEREST & RISK NOTE
We would like to point out that Apaton Finance GmbH, the owner of news.financial, as well as partners, authors or employees of Apaton Finance GmbH may hold shares in the aforementioned companies and that there may therefore be a conflict of interest. Further details can be found in our ´Conflict of Interest & Risk Disclosure´.


{{labelSign}}  Favorites
{{errorMessage}}

Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company